LabGenius's protein engineering platform integrates several technologies from the fields of machine learning, synthetic biology, and robotics. It uses computational methods to explore protein fitness landscapes and improve multiple drug properties simultaneously.

The discovery of protein therapeutics has historically been highly artisanal, relying heavily on humans for both experimental design and execution. This dependence is limiting because, as a species, we’re cognitively incapable of fully grasping the complexity of biological systems. LabGenius is pushing the boundaries of protein engineering through the development of EVA - a smart robotic platform capable of designing, conducting and critically, learning from its own experiments. The learning aspect means that EVA gets continuously smarter as it unpicks the genetic design rules that underpin life.

LabGenius is deploying EVA to develop novel antibody fragments in therapeutic areas, including solid tumours, where there's a distinct advantage over traditional antibody formats. EVA engineers high-value protein drug properties that currently remain a challenge, such as efficacy, potency, selectivity, and manufacturability.

The team at LabGenius are excited by this rapid experimentation and are looking at how the same principles can be applied more widely to find treatments for human diseases.

LabGenius represents a new generation of companies at the intersection of technology and biology, a category that we believe will overtake traditional industry over the next decades.

Founder Dr. James Field and his multidisciplinary team are integrating machine learning, synthetic biology and robotic automation in a platform that fundamentally rethinks and redesings the process of discovering protein-based drugs, making it much faster and more efficient. At scale, this will be a step-change in human’s ability to find cures for life threatening diseases and unlock the current industry bottleneck we are finding ourselves in.